These studies highlight the clear therapeutic applicability of rationally designed GLP-1/apelin hybrid molecules for the treatment of obesity and T2DM.
Sridhar et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: